Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction

British Journal of Clinical Pharmacology

Volumn 69, Issue 2, 2010, Pages 193-199

  Fang, Zhong Ze ^a,b   Zhang, Yan Yan ^a,b   Ge, Guang Bo ^a   Huo, Hong ^a   Liang, Si Cheng ^a   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Cytochrome P450 (CYP); Drug drug interaction; Noscapine; Time dependent inhibition; Warfarin

Indexed keywords

CYTOCHROME; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; NOSCAPINE; WARFARIN; ANTICOAGULANT AGENT; ANTITUSSIVE AGENT; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A INHIBITOR; UNSPECIFIC MONOOXYGENASE;

AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HUMAN; IC 50; KINETICS; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; ADULT; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMICAL MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; MALE; METABOLISM; MIDDLE AGED; TIME; TISSUE CULTURE TECHNIQUE;

ADULT; ANTICOAGULANTS; ANTITUSSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP3A INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, CHEMICAL; NOSCAPINE; TIME FACTORS; TISSUE CULTURE TECHNIQUES; WARFARIN;

EID: 75149152466     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03572.x     Document Type: Article

References (23)

1. Empey DW, Laitinen LA, Young GA, Bye CE, Hughes DTD. Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg and noscapine 30 mg using citric acid-induced cough in normal subjects. Eur J Clin Pharmacol 1979 16 : 393 397.
2. Ye KQ, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, Petros J, Joshi HC. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA 1998 95 : 1601 1606.
3. Landen JW, Han V, Wang MS, Davis T, Ciliax B, Wainer BH, Van Meir EG, Glass JD, Joshi HC, Archer DR. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 2004 10 : 5187 5201.
4. Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res 2007 67 : 3862 3870.
5. Aneja R, Dhiman N, Idnani J, Awasthi A, Arora SK, Chandra R, Joshi HC. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemoth Pharm 2007 60 : 831 839.
6. Ohlsson S, Holm L, Myrberg O, Sundstrom A, Yue QY. Noscapine may increase the effect of warfarin. Br J Clin Pharmacol 2008 65 : 277 278.
7. Scordo MG, Melhus H, Stjernberg E, Edvardsson AM, Wadelius M. Warfarin-noscapine interaction: a series of four case reports. Ann Pharmacother 2008 42 : 448 450.
8. Liu HX, Liu Y, Zhang JW, Li W, Liu HT, Yang L. UDP- glucuronosyltransferase 1A6 is the major isozyme responsible for protocatechuic aldehyde glucuronidation in human liver microsomes. Drug Metab Dispos 2008 36 : 1562 1569.
9. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951 193 : 265 275.
10. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 1964 239 : 2370 2385.
11. Zhang JW, Liu Y, Li W, Hao DC, Yang L. Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes. Eur J Clin Pharmacol 2006 62 : 497 502.
12. Zhang YY, Liu Y, Zhang JW, Ge GB, Wang LM, Sun J, Yang L. Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 2009 39 : 283 292.
13. Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007 35 : 246 255. (Pubitemid 46148737)
14. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002 30 : 1497 1503.
15. Ran YQ, He Y, Yang G, Johnson JLH, Yalkowsky SH. Estimation of aqueous solubility of organic compounds by using the general solubility equation. Chemosphere 2002 48 : 487 509.
16. Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 2005 60 : 508 518.
17. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997 73 : 67 74.
18. Karjalainen MJ, Neuvonen PJ, Backman JT. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. Drug Metab Dispos 2006 34 : 2091 2096.
19. Karlsson MO, Dahlstrom B, Eckernas SA, Johansson M, Alm AT. Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol 1990 39 : 275 279.
20. Idanpaan-Heikkila JE. Studies on fate of 3H-noscapine in mice and rats. Ann Med Exp Fenn 1968 46 : 201 206.
21. Kolilekas L, Anagnostopoulos GK, Lampaditis I, Eleftheriadis I. Potential interaction between telithromycin and warfarin. Ann Pharmacother 2004 38 : 1424 1427.
22. Takahashi H, Kashima T, Kimura S, Murata N, Takaba T, Iwade K, Abe T, Tainaka H, Yasumori T, Echizen H. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of in vitro approaches to predicting in vivo reduction of (S)-warfarin clearance. Drug Metab Dispos 1999 27 : 1179 1186.
23. Murray M. Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr Drug Metab 2000 1 : 67 84.